On October 16, 2026 Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, reported that it will host a virtual panel discussion, "The State of WEE1 Inhibition in Precision Oncology," on Tuesday, October 20, 2026, at 11 am ET.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Disrupting the DNA damage response has become a compelling therapeutic strategy in oncology in recent years and WEE1 inhibitors are among the most promising drugs being developed within this class. Ahead of the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, this panel will cover the underlying biology of WEE1, the selectivity challenge that has shaped the class, and what to watch in the months ahead, across scientific, clinical, and market perspectives.
Moderated by Solomon Wilcots, NFL broadcaster and former player for the Cincinnati Bengals, the panel will feature the following participants:
Dr. Alex Spira, Director of the Thoracic and Phase I Program at the Virginia Cancer Specialists Research Institute, Chief Scientific Officer of NEXT Oncology and Clinical Assistant Professor at Johns Hopkins School of Medicine.
Kevin DeGeeter Managing Director in equity research at Ladenburg Thalmann & Co. Inc.
Dr. Eugene Kennedy, Chief Medical Advisor of Aprea Therapeutics, Inc.
To register, please visit View Source
Aprea’s lead program, APR-1051, is an oral, small-molecule WEE1 kinase inhibitor being evaluated in the ongoing Phase 1 ACESOT-1051 study in patients with biomarker-defined advanced solid tumors.
(Press release, Aprea, OCT 16, 2026, View Source [SID1234673528])